# The COVID-19 and Cancer Consortium: NCI Administrative Supplement to P30 Cancer Center Support Grant (CCSG)

> **NIH NIH P30** · VANDERBILT UNIVERSITY MEDICAL CENTER · 2021 · $600,000

## Abstract

Project Summary
COVID-19, the disease caused by the SARS-coV-2 virus, has now affected nearly 100 million
people globally, with nearly 2 million deaths. Patients with cancer have a unique risk profile in this
pandemic. Many patients, especially those actively on treatment, have high levels of contact with
the health care system. This can include provider visits, phlebotomy, imaging, social work and
financial consultations, and infusion room visits for anti-cancer therapy and supportive care such
as blood transfusions. Despite heroic efforts to reduce viral transmission in these shared spaces,
patients are at an increased risk for COVID-19 exposure. Additionally, most cancer patients are
immunocompromised through the marrow toxic effects of anti-cancer drugs, supportive
medications such as steroids, and/or the cancer itself; and over 60 years of age, putting them in
the highest-risk category for COVID-19-related morbidity and mortality. Finally, incidences of
important comorbidities can be considerably elevated in several cancers, such as chronic
obstructive pulmonary disease in lung cancer or inflammatory bowel disease in colorectal cancer,
further exacerbating their vulnerability to this novel pathogen.
Given an acute lack of knowledge and concern for extreme vulnerability, the COVID-19 and
Cancer Consortium (CCC19) was formed in March 2020 to understand how the novel virus
affects cancer patients. While this national effort began organically, primarily through social
media, membership has quickly grown to over 450 healthcare professionals and patient
advocates representing over 125 institutions and organizations in the US, Canada, and Mexico.
Included in this membership are the majority of the NCI-designated Comprehensive Cancer
Centers, NCI-Designated Cancer Centers and large networks of community practices, many of
which are NCORP sites. The driving goal of the consortium is to collect prospective, granular,
uniformly organized information to help generate hypotheses for translational science, and to arm
treating providers with the most complete data resource as rapidly as possible on cancer patients
infected with COVID-19. As of January 2021, CCC19 has collected over 8000 case reports of
high analytical quality, and has published initial results in The Lancet, Cancer Discovery, Cancer
Cell, and Nature Cancer.
As the Research Coordinating Center for the consortium, we establish and propagate best
practices for governance, data collection, and data dissemination. We host the main data registry,
conduct data cleaning, quality assurance, and central data analysis, and will work with participant
institutions who choose to set up mirrored local databases.

## Key facts

- **NIH application ID:** 10332040
- **Project number:** 3P30CA068485-25S2
- **Recipient organization:** VANDERBILT UNIVERSITY MEDICAL CENTER
- **Principal Investigator:** JENNIFER A PIETENPOL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $600,000
- **Award type:** 3
- **Project period:** 2021-05-01 → 2025-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10332040

## Citation

> US National Institutes of Health, RePORTER application 10332040, The COVID-19 and Cancer Consortium: NCI Administrative Supplement to P30 Cancer Center Support Grant (CCSG) (3P30CA068485-25S2). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10332040. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*